Interestingly, although endogenous Bpifb4 expression was equally induced in all the heart layers, we found that LAV-BPIFB4 protein therapy promoted significant microvascular enhancements only in the subendocardial region, which is the most vulnerable to ischemia [37, 38]. This evidence concerns the gene BPIFB4 and ischemia.